“One-Two Punch”: Synergistic ß-Lactam Combinations forMycobacterium abscessusand Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes
Author(s) -
David C. Nguyen,
Khalid M Dousa,
Sebastian G. Kurz,
Sheldon T. Brown,
George L. Drusano,
Steven M. Holland,
Barry N. Kreiswirth,
W. Henry Boom,
Charles L. Daley,
Robert A. Bonomo
Publication year - 2021
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab535
Subject(s) - mycobacterium abscessus , peptidoglycan , microbiology and biotechnology , medicine , cephalosporin , lactam , enzyme , mycobacterium , antibiotics , biology , biochemistry , chemistry , pathology , tuberculosis , stereochemistry
Mycobacterium abscessus subsp. abscessus is one of the most difficult pathogens to treat and its incidence in disease is increasing. Dual β-lactam combinations act synergistically in vitro but are not widely employed in practice. A recent study shows that a combination of imipenem and ceftaroline significantly lowers the minimum inhibitory concentration of clinical isolates, despite both drugs targeting the same peptidoglycan synthesis enzymes. The underlying mechanism of this effect provides a basis for further investigations of dual β-lactam combinations in the treatment of M. abscessus subsp. abscessus, eventually leading to a clinical trial. Furthermore, dual β-lactam strategies may be explored for other difficult mycobacterial infections.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom